EFFICACY AND TOLERABILITY OF PRIVIGEN® (IGPRO10) IN PRIMARY AND SECONDARY IMMUNODEFICIENCIES - A MULTICENTER OBSERVATIONAL STUDY

被引：0
|
作者：
Otremba, B.
Slawik, H. R.
Tschechne, B. [1 ]
Lotichius, P.
Pfruender, D. [2 ]
机构：
[1] Tagesklin Krankenhaus, Neustadt A Rbge, Germany
[2] CSL Behring, Hattersheim, Germany
来源：
JOURNAL OF CLINICAL IMMUNOLOGY | 2012年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
下载
收藏
页码：158 / 159
页数：2
相关论文
共 50 条
  • [1] Efficacy and tolerability of Privigen® (IgPro10) in primary and secondary immunodeficiencies - A multicenter observational study
    Otremba, B.
    Slawik, H. R.
    Tschechne, B.
    Lotichius, P.
    Pfruender, D.
    PROCEEDINGS OF THE 15TH MEETING OF THE EUROPEAN SOCIETY IMMUNODEFICIENCIES (ESID), 2013, : 15 - 18
  • [2] Efficacy and Tolerability of Privigen in Secondary Immunodeficiencies - Results from a Multicenter Observational Study
    Slawik, H. R.
    Plath, M.
    Reiser, M.
    Otremba, B.
    Lotichius, P.
    Pfruender, D.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S296 - S296
  • [3] Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study
    Tomohiro Morio
    Kenji Gotoh
    Tomoyuki Imagawa
    Kimio Morita
    Hidenori Ohnishi
    Kozo Yasui
    Jutta Hofmann
    John Philip Lawo
    Amgad Shebl
    Mikhail A. Rojavin
    International Journal of Hematology, 2021, 113 : 921 - 929
  • [4] Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study
    Morio, Tomohiro
    Gotoh, Kenji
    Imagawa, Tomoyuki
    Morita, Kimio
    Ohnishi, Hidenori
    Yasui, Kozo
    Hofmann, Jutta
    Lawo, John Philip
    Shebl, Amgad
    Rojavin, Mikhail A.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (06) : 921 - 929
  • [5] Efficacy of different immunoglobulin doses in the prevention of severe and serious infections in patients with secondary immunodeficiencies - results from a multicenter observational study with Privigen®
    Ehlers, H. -U.
    Innig, G.
    Otremba, B.
    Plath, M.
    Slawik, H. R.
    Reiser, M.
    Weide, R.
    Pfruender, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 221 - +
  • [6] Privigen® in secondary immunodeficiencies - interim analysis of a multicenter non-interventional study in Germany
    Plath, M.
    Slawik, H. R.
    Reiser, M.
    Otremba, B.
    Pfruender, D.
    Oncology Research and Treatment, 2015, 38 : 77 - 77
  • [7] A multicenter observational study on the efficacy and tolerability of Privigen® (intravenous immunoglobulin preparation) - Interim analysis with focus on immune thrombocytopenia (ITP)
    Tschechne, B.
    Otremba, B.
    Lotichius, P.
    Pfruender, D.
    ONKOLOGIE, 2011, 34 : 170 - 171
  • [8] A multicenter observational study on the efficacy and tolerability of Privigen® in patients with chronic lymphocytic leukaemia (CLL), hypogammaglobulinemia and recurrent bacterial infections
    Otremba, B.
    Lotichius, P.
    Pfruender, D.
    ONKOLOGIE, 2013, 36 : 57 - 58
  • [9] POPULATION PHARMACOKINETIC ANALYSIS OF IGPRO10 IN JAPANESE PATIENTS WITH PRIMARY IMMUNODEFICIENCY.
    Luo, D.
    Tortorici, M.
    Hofmann, J.
    Rojavin, M.
    Baheti, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S94 - S94
  • [10] Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen<(C)>) stabilized with L-proline
    Cramer, M.
    Frei, R.
    Sebald, A.
    Mazzoletti, P.
    Maeder, W.
    VOX SANGUINIS, 2009, 96 (03) : 219 - 225
12345